$BMY

Hospitals and the federal government dispute the cost of a new 340B rebate pilot, with hospitals estimating over $1 billion annually and HRSA projecting $537 million. The American Hospital Association and others sued HHS and HRSA to block the program, set to start in 2027. Drugmakers AbbVie, Bristol-Myers Squibb, and Boehringer Ingelheim, along with PhRMA, have joined the lawsuit. The program affects 21 drugs from 10 manufacturers, including Eliquis and Jardiance.

Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ) are compared as long-term healthcare investments. BMY reported FY 2025 revenue of $48.2B, net income of $7.1B, and a 4.16% dividend yield. JNJ reported FY 2025 revenue of $94.2B, net income of $26.8B, and a 2.08% dividend yield. Both face regulatory and patent challenges, with JNJ offering diversification and stability, while BMY provides higher income but more risk.

Bristol Myers Squibb (BMY) increased its quarterly dividend to $0.63, marking 17 consecutive annual raises. The yield is 4.2% based on the current share price. Q2 EPS exceeded estimates, leading to raised 2026 guidance. Growth portfolio sales rose 15%, but older drugs like Revlimid and Pomalyst declined. The dividend's future depends on new drugs replacing Eliquis, which faces patent expiry in 2028. The company has $43.1 billion in debt.

Bristol-Myers Squibb (BMY) shares rose 40% over the past year, driven by new drug revenue growth and raised 2026 EPS guidance to $6.75-$7.00. The company's Growth Portfolio revenue increased 15% YoY to $7.6B, with key products like Reblozyl, Breyanzi, and Camzyos showing strong growth. However, legacy products declined, with Revlimid revenue down 49%. BMY trades at 9.36x forward earnings, reflecting investor concerns about older drug sales and R&D costs.

A Democratic report claims Trump's investment in drugmakers surged from $1.7M in 2024 to $56.2M by 2025, including $39.1M in firms benefiting from Medicare exemptions. Purchases totaled $2.55M before the law's passage, including $950K on the Senate vote day and $1M in AbbVie stock post-law. The White House denies conflicts of interest, stating the portfolio is independently managed.

Bristol-Myers Squibb (BMY) is leveraging AI to accelerate drug development, cutting timelines and costs. The company's 'Predict First' approach and partnerships with Nvidia (NVDA) and Anthropic aim to enhance research. Despite strong Q2 2026 results, BMY trades at a 65% discount to the S&P 500, offering potential value. The pharma sector's low valuations and AI integration could drive future returns.

Bristol Myers Squibb, AbbVie, and Boehringer Ingelheim are seeking to intervene in a lawsuit challenging a federal drug rebate pilot program. The companies argue the US Health Resources & Services Administration cannot fully defend their interests in the 340B Rebate Model Pilot, set to launch January 1, 2025. The program aims to change how manufacturers discount certain medicines under the 340B Drug Pricing Program.

Bristol Myers Squibb's experimental pulmonary fibrosis drug admilparant met the main goal at 60 mg in a phase 3 trial but missed the target at 120 mg. The company reported topline results, with detailed data to be presented later. Both doses were well tolerated, but one death occurred in the 120 mg group. BMS shares fell about 3% in early trading.

Perrigo (PRGO) gained 3.77% on a $10M lawsuit settlement. Gilead (GILD) rose 3.8% after an analyst raised its price target. Kroger (KR) increased 3.87% despite 3K job cuts. Bristol-Myers (BMY) climbed 4.61% on positive drug trial results.

Bristol Myers Squibb Co. shares rose 4.61% to $59.28 Wednesday, outperforming broader market declines. This ended a four-day losing streak for the company. The S&P 500 and Dow Jones indices fell 1.11% and 0.09%, respectively.